AMPEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 03:35):

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States...

Stats
本日の出来高	643.00
平均出来高	64 912.00
時価総額	267 079
EPS	$0 ( 2024-03-25 )
次の収益日	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-09	Buchi J Kevin	Buy	21 858	Common Stock
2023-06-08	Buchi J Kevin	Buy	25 000	Common Stock
2023-05-24	Martino Michael A	Buy	76 890	Common Stock
2023-05-16	Buchi J Kevin	Buy	32 534	Common Stock
2023-05-15	Buchi J Kevin	Buy	44 026	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 6 813 241 \| Sell: 1 519 396

Ampio Pharmaceuticals Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ampio Pharmaceuticals Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-10.66

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-10.66

FY	2022
収益:	$0
総利益:	$-2.08M (0.00 %)
EPS:	$-11.24

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.482

Financial Reports:

No articles found.

Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.